Results 281 to 290 of about 6,774,149 (386)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

A Potential Role for JAK Inhibitors in Refractory Photoaggravated Atopic Dermatitis. [PDF]

Photodermatol Photoimmunol Photomed
Warner-Levy J, Khoursheed L, Parkin D, Ayer J.   +3 more
europepmc   +1 more source

A novel and high-performance tumor inhibitor of La, N co-doped carbon dots for U251 and LN229 cells

Xinyun Ye, Huanglian Zhong, Lin Liu, J. H. Huang, Zhengcai Xia, Zhiji Tang, Wenjin Wei, Weilong Huang, Yuwei Ye, Qiuhua Jiang   +9 more
openalex   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Advances in Targeting BCR-ABL^T315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]

Molecules
Tuzikiewicz A, Wawrzyniak W, Kutner A, Żołek T.   +3 more
europepmc   +1 more source

Myoglobin inhibits proliferation of cultured human proximal tubular (HK-2) cells

, 1996
Mineo Iwata, Richard A. Zager
openalex   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition. [PDF]

Cell Oncol (Dordr)
van der Noord VE, McLaughlin RP, Karuntu JS, He J, Timmermans AM, Basnet SKC, Long Y, Diab SAH, Tadesse S, Proost N, van Gerwen B, Siteur B, van de Ven M, Pont C, Le Dévédec SE, Martens JWM, Wang S, Zhang Y, van de Water B.   +18 more
europepmc   +1 more source